[PDF][PDF] Almanaques ou a sabedoria e as tarefas do tempo
MV Guerreiro, JDP Correia - Revista do Instituto de Cultura e …, 1986 - cvc.instituto-camoes.pt
A divisão do ano em função dos fenómenos nele observáveis e respectivo registo, o que,
em suma, constitui a parte nuclear do que chamamos almanaque, recua a épocas …
em suma, constitui a parte nuclear do que chamamos almanaque, recua a épocas …
Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma
…, L Lopez Corral, JM Sanchez, M Guerreiro… - Cancer …, 2021 - Wiley Online Library
Tisagenlecleucel (tisa‐cel) is a second‐generation autologous CD19‐targeted chimeric
antigen receptor (CAR) T‐cell therapy approved for relapsed/refractory (R/R) large B‐cell …
antigen receptor (CAR) T‐cell therapy approved for relapsed/refractory (R/R) large B‐cell …
[HTML][HTML] Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
…, RH Morales, V Ortiz-Maldonado, M Guerreiro… - …, 2023 - ncbi.nlm.nih.gov
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-targeted chimeric
antigen receptor (CAR) T cells approved for relapsed/refractory (R/R) large B-cell …
antigen receptor (CAR) T cells approved for relapsed/refractory (R/R) large B-cell …
Adiponectin is a negative regulator of antigen‐activated T cells
…, A Jenke, M Rother, M Guerreiro… - European journal of …, 2011 - Wiley Online Library
Adiponectin (APN), a cytokine constitutively produced in fat tissue, has been shown to exert
anti‐inflammatory effects in various disease models. While the influence of APN on …
anti‐inflammatory effects in various disease models. While the influence of APN on …
SARS‐CoV‐2‐reactive antibody detection after SARS‐CoV‐2 vaccination in hematopoietic stem cell transplant recipients: prospective survey from the Spanish …
…, C Solano, B Ferrer‐Lores, M Guerreiro… - American Journal of …, 2022 - Wiley Online Library
This is a multicenter prospective observational study that included a large cohort (n = 397)
of allogeneic (allo‐HSCT; (n = 311) and autologous (ASCT) hematopoietic stem cell …
of allogeneic (allo‐HSCT; (n = 311) and autologous (ASCT) hematopoietic stem cell …
One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients
…, A Roldán-Pérez, B Ferrer, M Guerreiro… - Blood cancer …, 2023 - nature.com
The long-term clinical efficacy of SARS-CoV-2 vaccines according to antibody response in
immunosuppressed patients such as hematological patients has been little explored. A …
immunosuppressed patients such as hematological patients has been little explored. A …
[HTML][HTML] Prospective randomized study comparing myeloablative unrelated umbilical cord blood transplantation versus HLA-haploidentical related stem cell …
…, A Balaguer-Roselló, M Guerreiro… - Biology of Blood and …, 2020 - Elsevier
In this prospective randomized study, we compared the outcomes of single-unit umbilical cord
blood transplantation (UCBT) and unmanipulated haploidentical stem cell transplantation (…
blood transplantation (UCBT) and unmanipulated haploidentical stem cell transplantation (…
Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia
…, F Giglio, A Facal, F Lorentino, M Guerreiro… - Bone Marrow …, 2022 - nature.com
Post-transplant cyclophosphamide (PTCy) has emerged as a promising graft-versus-host
disease (GvHD) prophylaxis in allogeneic hematopoietic stem cell transplantation (allo-HSCT). …
disease (GvHD) prophylaxis in allogeneic hematopoietic stem cell transplantation (allo-HSCT). …
Human peripheral blood and bone marrow Epstein–Barr virus‐specific T‐cell repertoire in latent infection reveals distinct memory T‐cell subsets
EBV infection leads to life‐long viral persistence. Although EBV infection can result in chronic
disease and malignant transformation, most carriers remain disease‐free as a result of …
disease and malignant transformation, most carriers remain disease‐free as a result of …
Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell …
…, R Hernani, I Lorenzo, A Pérez, M Guerreiro… - Bone Marrow …, 2020 - nature.com
Following the success of posttransplant cyclophosphamide (PT-CY) as graft-versus-host
disease (GVHD) prophylaxis in haploidentical transplantation, this prevention strategy has …
disease (GVHD) prophylaxis in haploidentical transplantation, this prevention strategy has …